Novo's CEO Mike Doustdar defended the company's diversification strategy and signaled openness to M&A deals beyond obesity treatment, following investor disappointment at Monday's Capital Markets Day. The pharmaceutical giant faces mounting competition in weight-loss drugs from rivals like Eli Lilly and plans to launch five multi-blockbuster drugs by 2030 while expanding into blood disorders, liver disease, and cardiovascular areas.